Home/Genelux/James L. Tyree

JL

James L. Tyree

Former Chief Financial Officer

Therapeutic Areas

Genelux Pipeline

Drug	Indication	Phase
Olvi-Vec (olvimulogene nanivacirepvec)	Platinum-Resistant/Refractory Ovarian Cancer	Phase 2/3
Olvi-Vec	Small Cell Lung Cancer (SCLC)	Phase 2
GLX-401	Undisclosed Solid Tumors	Preclinical

Leadership Team at Genelux

Thomas Zindrick, J.D., M.B.A.

Chairman of the Board, President & Chief Executive Officer

Dr. Paul Fischer, M.D.

Former Chief Medical Officer

Dr. Aladar A. Szalay, Ph.D.

Founder and Chief Scientific Officer

View full Genelux profile